Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 1.00 |
| ▸ | MAOB | P27338 | 9/20 | 0.61 |
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837382 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAHDAC6CYP2C19 | |
| SCHEMBL15137021 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOAHDAC6CYP2C19 | |
| Hydrochloric Acid SCHEMBL527164 | 0.98 | KDM1A (0.97) | KDM1AMAOBMAOAHDAC6CYP2C19 | |
| Hydrochloric Acid SCHEMBL16626192 | 0.98 | KDM1A (0.97) | KDM1AMAOBMAOAHDAC6CYP2C19 | |
| SCHEMBL527018 | 0.77 | KDM1A (0.62) | KDM1AMAOBMAOAHSD17B10 | |
| SCHEMBL6837457 | 0.77 | KDM1A (0.62) | KDM1AMAOBMAOAHSD17B10 | |
| SCHEMBL527017 | 0.77 | KDM1A (0.62) | KDM1AMAOBMAOAHSD17B10 | |
| SCHEMBL15136700 | 0.77 | KDM1A (0.62) | KDM1AMAOBMAOAHSD17B10 | |
| SCHEMBL527284 | 0.77 | KDM1A (0.62) | KDM1AMAOBMAOAHSD17B10 | |
| SCHEMBL529679 | 0.77 | KDM1A (1.00) | KDM1AMAOBMAOAHDAC6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | claimed |
| US-9676701-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2017-06-13 | — | — | US | claimed |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. | 2016-02-25 | — | — | US | claimed |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-08-01 | — | — | US | claimed |
| EP-2598480-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | claimed |
| WO-2012013727-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| WO-2016029262-A1 | COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR | UNIVERSITY OF CANBERRA (AU) | 2016-03-03 | — | — | WO | disclosed |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. | 2016-02-25 | — | — | US | disclosed |
| US-9006449-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2015-04-14 | — | — | US | disclosed |
| WO-2014205511-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | UNIVERSITY OF CANBERRA (AU) | 2014-12-31 | — | — | WO | disclosed |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-08-01 | — | — | US | disclosed |
| EP-2598480-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013727-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | KDM1A 8/4885MAOB 36/4885MAOA 54/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | KDM1A 6/4885MAOB 2932/4885MAOA 3132/4885 |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAOB 173/4885MAOA 141/4885 |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAOB 173/4885MAOA 141/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | KDM1A 2/4885MAOB 3928/4885MAOA 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.